AstraZeneca’s Ultomiris hits primary endpoint for PhIII NMOSD study

AstraZeneca caught a trio of recent wins — scoring an expanded indication for its breast cancer drug Enhertu, nailing Farxiga’s Phase III win earlier this week, and now, another trial win.

The UK pharma said Thursday that its long-acting C5 complement inhibitor drug Ultomiris (ravulizumab-cwvz) hit on its primary endpoint...

Click to view original post